Published in Mol Pharm on May 30, 2008
RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43
Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev (2009) 3.17
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev (2009) 3.08
Toxicity and cellular uptake of gold nanoparticles: what we have learned so far? J Nanopart Res (2010) 2.70
The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials (2011) 2.45
Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci U S A (2010) 2.21
Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nat Nanotechnol (2010) 2.00
Nanoparticles and the immune system. Endocrinology (2009) 1.79
PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett (2012) 1.77
Progress in microRNA delivery. J Control Release (2013) 1.58
A synthetic fibrin cross-linking polymer for modulating clot properties and inducing hemostasis. Sci Transl Med (2015) 1.51
Impact of silica nanoparticle design on cellular toxicity and hemolytic activity. ACS Nano (2011) 1.47
Biodistribution of TNF-alpha-coated gold nanoparticles in an in vivo model system. Nanomedicine (Lond) (2009) 1.44
Targeted delivery of amikacin into granuloma. Am J Respir Crit Care Med (2010) 1.42
Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles. PLoS One (2009) 1.31
Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. Nat Rev Clin Oncol (2010) 1.30
Challenges in development of nanoparticle-based therapeutics. AAPS J (2012) 1.28
Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res (2012) 1.24
Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine (2012) 1.24
Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials (2011) 1.20
The role of surface functionality in determining nanoparticle cytotoxicity. Acc Chem Res (2013) 1.17
Translational considerations for cancer nanomedicine. J Control Release (2010) 1.12
Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth. Mol Ther (2012) 1.10
Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects. Nano Today (2014) 1.09
Slow CCL2-dependent translocation of biopersistent particles from muscle to brain. BMC Med (2013) 1.09
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev (2015) 1.08
Protein corona significantly reduces active targeting yield. Chem Commun (Camb) (2013) 1.05
In vivo evaluation of safety of nanoporous silicon carriers following single and multiple dose intravenous administrations in mice. Int J Pharm (2010) 1.05
Cytokines as biomarkers of nanoparticle immunotoxicity. Chem Soc Rev (2013) 1.05
Nanoparticle characterization: state of the art, challenges, and emerging technologies. Mol Pharm (2013) 1.04
Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2012) 1.02
Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects. Part Fibre Toxicol (2011) 1.02
Fibrin-binding, peptide amphiphile micelles for targeting glioblastoma. Biomaterials (2013) 1.00
Enhancing Cell therapies from the Outside In: Cell Surface Engineering Using Synthetic Nanomaterials. Nano Today (2011) 0.96
Intratumoral drug delivery with nanoparticulate carriers. Pharm Res (2011) 0.95
Ambiguities in applying traditional Limulus amebocyte lysate tests to quantify endotoxin in nanoparticle formulations. Nanomedicine (Lond) (2010) 0.95
The dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity. Front Immunol (2013) 0.94
Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concerns. Cancer Res (2012) 0.94
Steering carbon nanotubes to scavenger receptor recognition by nanotube surface chemistry modification partially alleviates NFκB activation and reduces its immunotoxicity. ACS Nano (2011) 0.93
Formation of stable nanocarriers by in situ ion pairing during block-copolymer-directed rapid precipitation. Mol Pharm (2012) 0.92
Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis. Expert Opin Drug Deliv (2011) 0.92
Effects of block copolymer properties on nanocarrier protection from in vivo clearance. J Control Release (2012) 0.92
Determinants of the thrombogenic potential of multiwalled carbon nanotubes. Biomaterials (2011) 0.92
Zwitterionic chitosan derivative, a new biocompatible pharmaceutical excipient, prevents endotoxin-mediated cytokine release. PLoS One (2012) 0.92
Immunosuppressive and anti-inflammatory properties of engineered nanomaterials. Br J Pharmacol (2014) 0.90
Macrophage scavenger receptor A mediates the uptake of gold colloids by macrophages in vitro. Nanomedicine (Lond) (2011) 0.89
Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid Tumors. J Pharm Innov (2014) 0.89
Carbon nanotubes in hyperthermia therapy. Adv Drug Deliv Rev (2013) 0.89
Influence of polyethylene glycol density and surface lipid on pharmacokinetics and biodistribution of lipid-calcium-phosphate nanoparticles. Biomaterials (2014) 0.89
Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon. Mol Ther Nucleic Acids (2016) 0.89
NH2+ implantations induced superior hemocompatibility of carbon nanotubes. Nanoscale Res Lett (2013) 0.87
Nanoparticulate adjuvants and delivery systems for allergen immunotherapy. J Biomed Biotechnol (2012) 0.87
Cellular Uptake and Intracellular Cargo Release From Dextran Based Nanogel Drug Carriers. J Nanotechnol Eng Med (2013) 0.85
Biotargeted nanomedicines for cancer: six tenets before you begin. Nanomedicine (Lond) (2013) 0.85
Nanoparticle Uptake: The Phagocyte Problem. Nano Today (2015) 0.84
Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology. J Pharmacol Exp Ther (2013) 0.84
Design of siRNA Therapeutics from the Molecular Scale. Pharmaceuticals (Basel) (2013) 0.84
Peptides and proteins used to enhance gold nanoparticle delivery to the brain: preclinical approaches. Int J Nanomedicine (2015) 0.84
Triggered Nanoparticles as Therapeutics. Nano Today (2013) 0.83
Re-examining the size/charge paradigm: differing in vivo characteristics of size- and charge-matched mesoporous silica nanoparticles. J Am Chem Soc (2013) 0.83
Cationic nanocarriers induce cell necrosis through impairment of Na(+)/K(+)-ATPase and cause subsequent inflammatory response. Cell Res (2015) 0.83
Theranostic nanoparticles carrying doxorubicin attenuate targeting ligand specific antibody responses following systemic delivery. Theranostics (2015) 0.82
Mitigation of quantum dot cytotoxicity by microencapsulation. PLoS One (2011) 0.82
Synthetic Strategies for Engineering Intravenous Hemostats. Bioconjug Chem (2015) 0.82
Gold nanoprobes for theranostics. Nanomedicine (Lond) (2011) 0.82
Carbon black particle exhibits size dependent toxicity in human monocytes. Int J Inflam (2014) 0.82
Intravenous Administration of Cilostazol Nanoparticles Ameliorates Acute Ischemic Stroke in a Cerebral Ischemia/Reperfusion-Induced Injury Model. Int J Mol Sci (2015) 0.81
Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of morphine relapse. Sci Rep (2015) 0.81
Effect of pullulan nanoparticle surface charges on HSA complexation and drug release behavior of HSA-bound nanoparticles. PLoS One (2012) 0.81
Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems. AAPS J (2011) 0.81
Silica-coated Gd(DOTA)-loaded protein nanoparticles enable magnetic resonance imaging of macrophages. J Mater Chem B Mater Biol Med (2015) 0.80
Fluorescent nanodiamonds as a relevant tag for the assessment of alum adjuvant particle biodisposition. BMC Med (2015) 0.80
In vitro and in vivo biocompatibility of apatite-coated magnetite nanoparticles for cancer therapy. J Mater Sci Mater Med (2013) 0.79
Biodegradable optode-based nanosensors for in vivo monitoring. Anal Chem (2012) 0.79
Physically facilitating drug-delivery systems. Ther Deliv (2012) 0.79
Induced T cell cytokine production is enhanced by engineered nanoparticles. Nanotoxicology (2013) 0.79
Immunotoxicological impact of engineered nanomaterial exposure: mechanisms of immune cell modulation. Toxicol Mech Methods (2013) 0.78
Plasma proteins interaction with curcumin nanoparticles: implications in cancer therapeutics. Curr Drug Metab (2013) 0.78
Stimulating antitumor immunity with nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2014) 0.78
Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer. Sci Rep (2015) 0.78
Value of phagocyte function screening for immunotoxicity of nanoparticles in vivo. Int J Nanomedicine (2015) 0.78
The role of autophagy as a mechanism of toxicity induced by multi-walled carbon nanotubes in human lung cells. Int J Mol Sci (2014) 0.78
CdTe quantum dots induce activation of human platelets: implications for nanoparticle hemocompatibility. Int J Nanomedicine (2015) 0.78
Terminal PEGylated DNA-Gold Nanoparticle Conjugates Offering High Resistance to Nuclease Degradation and Efficient Intracellular Delivery of DNA Binding Agents. ACS Appl Mater Interfaces (2015) 0.78
Protein Adsorption Patterns and Analysis on IV Nanoemulsions-The Key Factor Determining the Organ Distribution. Pharmaceutics (2012) 0.78
Dual-function theranostic nanoparticles for drug delivery and medical imaging contrast: perspectives and challenges for use in lung diseases. Drug Deliv Transl Res (2013) 0.78
Engineered metal based nanoparticles and innate immunity. Clin Mol Allergy (2015) 0.78
Recapitulation of complex transport and action of drugs at the tumor microenvironment using tumor-microenvironment-on-chip. Cancer Lett (2015) 0.78
Critical questions in development of targeted nanoparticle therapeutics. Regen Biomater (2016) 0.77
Use of aerosol route to fabricate positively charged Au/Fe3O4 Janus nanoparticles as multifunctional nanoplatforms. Sci Rep (2016) 0.77
Nanotoxicity: An Interplay of Oxidative Stress, Inflammation and Cell Death. Nanomaterials (Basel) (2015) 0.77
Influence of Molecular Structure on the In Vivo Performance of Flexible Rod Polyrotaxanes. Biomacromolecules (2016) 0.77
C60 fullerene localization and membrane interactions in RAW 264.7 immortalized mouse macrophages. Nanoscale (2016) 0.77
Effect of nanoparticles binding β-amyloid peptide on nitric oxide production by cultured endothelial cells and macrophages. Int J Nanomedicine (2013) 0.77
Facilitating Translational Nanomedicine via Predictive Safety Assessment. Mol Ther (2017) 0.77
Differential Protein Adsorption and Cellular Uptake of Silica Nanoparticles Based on Size and Porosity. ACS Appl Mater Interfaces (2016) 0.76
Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model. PLoS One (2016) 0.76
MRI of High-Glucose Metabolism Tumors: a Study in Cells and Mice with 2-DG-Modified Superparamagnetic Iron Oxide Nanoparticles. Mol Imaging Biol (2016) 0.76
Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future. Toxicol Appl Pharmacol (2016) 0.76
Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment. Cancer Treat Rev (2016) 0.76
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm (2005) 7.53
Immunological properties of engineered nanomaterials. Nat Nanotechnol (2007) 5.59
Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol (2007) 3.75
PEG-modified gold nanorods with a stealth character for in vivo applications. J Control Release (2006) 3.74
Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv (2004) 3.65
Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release (2000) 3.07
Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol (2005) 2.56
Platelet phagocytosis and aggregation. J Cell Biol (1965) 2.27
The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. Adv Colloid Interface Sci (2007) 2.22
The role of complement in inflammation and phagocytosis. Immunol Today (1991) 2.04
In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur J Pharm Sci (2005) 1.72
Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug Chem (2007) 1.71
Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol (2003) 1.63
Characterization of nanoparticles for therapeutics. Nanomedicine (Lond) (2007) 1.62
In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes. J Biol Chem (1985) 1.55
Macrophage uptake of core-shell nanoparticles surface modified with poly(ethylene glycol). Langmuir (2006) 1.37
Nanoconjugate based on polymalic acid for tumor targeting. Chem Biol Interact (2007) 1.22
Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles. Pharm Res (2005) 1.21
Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. Int J Pharm (2007) 1.20
Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J Control Release (2001) 1.20
Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J Drug Target (2007) 1.14
Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. J Biomed Mater Res A (2006) 1.13
Gating the radical hemoglobin to macrophages: the anti-inflammatory role of CD163, a scavenger receptor. Antioxid Redox Signal (2007) 1.09
Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target (1996) 1.09
Investigations on the toxicological profile of functionalized fifth-generation poly (propylene imine) dendrimer. J Pharm Pharmacol (2006) 1.03
Complement activation by core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide. Pharm Res (2006) 1.02
Influence of PAMAM dendrimers on human red blood cells. Bioelectrochemistry (2004) 1.02
Apoptosis: the physiologic pathway of cell death. Hosp Pract (Off Ed) (1993) 1.02
Metalloproteinase and cytokine production by THP-1 macrophages following exposure to chitosan-DNA nanoparticles. Biomaterials (2005) 1.01
Interaction of PLGA nanoparticles with human blood constituents. Colloids Surf B Biointerfaces (2005) 1.01
Protein adsorption patterns on poloxamer- and poloxamine-stabilized solid lipid nanoparticles (SLN). Eur J Pharm Biopharm (2005) 1.00
Novel function of complement C3d as an autologous helper T-cell target. Immunol Cell Biol (2008) 0.99
Hemolytic effects of water-soluble fullerene derivatives. J Med Chem (2004) 0.98
DNA transfection and transfected cell viability using amphipathic asymmetric dendrimers. Int J Pharm (2000) 0.98
PLGA:poloxamer and PLGA:poloxamine blend nanostructures as carriers for nasal gene delivery. J Control Release (2006) 0.92
Water-soluble carbosilane dendrimers: synthesis biocompatibility and complexation with oligonucleotides; evaluation for medical applications. Chemistry (2007) 0.91
Coating of cationized protein on engineered nanoparticles results in enhanced immune responses. Int J Pharm (2002) 0.90
Receptor-mediated gene delivery into antigen presenting cells using mannosylated chitosan/DNA nanoparticles. J Nanosci Nanotechnol (2006) 0.89
Development of phosphorylated glucomannan-coated chitosan nanoparticles as nanocarriers for protein delivery. J Nanosci Nanotechnol (2006) 0.89
Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption. J Nanosci Nanotechnol (2006) 0.87
Immunological properties of engineered nanomaterials. Nat Nanotechnol (2007) 5.59
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev (2009) 3.08
Nanotechnology safety concerns revisited. Toxicol Sci (2007) 2.41
Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomedicine (2008) 1.99
Characterization of nanoparticles for therapeutics. Nanomedicine (Lond) (2007) 1.62
Redefining the requisite lipopolysaccharide structure in Escherichia coli. ACS Chem Biol (2006) 1.38
Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory. Integr Biol (Camb) (2013) 1.30
Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 1.30
Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metab Dispos (2008) 1.24
Induction of autophagy in porcine kidney cells by quantum dots: a common cellular response to nanomaterials? Toxicol Sci (2008) 1.23
Fullerenol cytotoxicity in kidney cells is associated with cytoskeleton disruption, autophagic vacuole accumulation, and mitochondrial dysfunction. Toxicol Appl Pharmacol (2010) 1.20
Method for analysis of nanoparticle hemolytic properties in vitro. Nano Lett (2008) 1.20
Translational considerations for cancer nanomedicine. J Control Release (2010) 1.12
Lack of significant dermal penetration of titanium dioxide from sunscreen formulations containing nano- and submicron-size TiO2 particles. Toxicol Sci (2010) 1.11
Nanoparticle size and surface charge determine effects of PAMAM dendrimers on human platelets in vitro. Mol Pharm (2011) 1.01
Single amino acid substitutions in either YhjD or MsbA confer viability to 3-deoxy-d-manno-oct-2-ulosonic acid-depleted Escherichia coli. Mol Microbiol (2007) 0.98
Ambiguities in applying traditional Limulus amebocyte lysate tests to quantify endotoxin in nanoparticle formulations. Nanomedicine (Lond) (2010) 0.95
Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion. J Control Release (2013) 0.93
Measurement of 15N relaxation in deuterated amide groups in proteins using direct nitrogen detection. J Biomol NMR (2006) 0.92
Activation of the MAP kinase cascade by exogenous calcium-sensing receptor. Mol Cell Endocrinol (2003) 0.89
Macrophage scavenger receptor A mediates the uptake of gold colloids by macrophages in vitro. Nanomedicine (Lond) (2011) 0.89
Nanomedicines: addressing the scientific and regulatory gap. Ann N Y Acad Sci (2014) 0.88
The tail of KdsC: conformational changes control the activity of a haloacid dehalogenase superfamily phosphatase. J Biol Chem (2009) 0.88
Dendrimer-induced leukocyte procoagulant activity depends on particle size and surface charge. Nanomedicine (Lond) (2011) 0.87
Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J Control Release (2013) 0.87
Biotargeted nanomedicines for cancer: six tenets before you begin. Nanomedicine (Lond) (2013) 0.85
Spin-state selection for increased confidence in cross-correlation rates measurements. J Biomol NMR (2005) 0.85
Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics. Expert Opin Drug Deliv (2015) 0.83
Choice of method for endotoxin detection depends on nanoformulation. Nanomedicine (Lond) (2013) 0.80
Inhibition of phosphoinositol 3 kinase contributes to nanoparticle-mediated exaggeration of endotoxin-induced leukocyte procoagulant activity. Nanomedicine (Lond) (2013) 0.80
Synergistic combination therapy with nanoliposomal C6-ceramide and vinblastine is associated with autophagy dysfunction in hepatocarcinoma and colorectal cancer models. Cancer Lett (2013) 0.80
Polymeric curcumin nanoparticle pharmacokinetics and metabolism in bile duct cannulated rats. Mol Pharm (2013) 0.79
Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics. Expert Opin Biol Ther (2015) 0.78
Analysis of fullerene-based nanomaterial in serum matrix by CE. Electrophoresis (2007) 0.75
Quantitative analysis of PEG-functionalized colloidal gold nanoparticles using charged aerosol detection. Anal Bioanal Chem (2015) 0.75